CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 38 filers reported holding CUE BIOPHARMA INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $722,170 | +11.3% | 313,987 | +76.6% | 0.00% | – |
Q2 2023 | $649,120 | +52674.0% | 177,841 | -48.4% | 0.00% | -100.0% |
Q1 2023 | $1,230 | +15.4% | 344,612 | -7.9% | 0.00% | 0.0% |
Q4 2022 | $1,066 | -99.9% | 373,982 | -15.1% | 0.00% | 0.0% |
Q3 2022 | $982,000 | -34.5% | 440,383 | -26.9% | 0.00% | 0.0% |
Q2 2022 | $1,499,000 | +154.9% | 602,205 | +399.9% | 0.00% | – |
Q1 2022 | $588,000 | -54.5% | 120,470 | +5.5% | 0.00% | -100.0% |
Q4 2021 | $1,292,000 | +7.4% | 114,204 | +38.3% | 0.00% | 0.0% |
Q3 2021 | $1,203,000 | -55.0% | 82,553 | -64.0% | 0.00% | -50.0% |
Q2 2021 | $2,672,000 | +179.5% | 229,333 | +192.6% | 0.00% | +100.0% |
Q1 2021 | $956,000 | -78.9% | 78,376 | -78.4% | 0.00% | -66.7% |
Q4 2020 | $4,535,000 | +67.0% | 362,523 | +100.9% | 0.00% | 0.0% |
Q3 2020 | $2,716,000 | -50.0% | 180,465 | -18.6% | 0.00% | -57.1% |
Q2 2020 | $5,431,000 | +4541.9% | 221,583 | +1491.3% | 0.01% | – |
Q3 2019 | $117,000 | +36.0% | 13,925 | +25.5% | 0.00% | – |
Q1 2019 | $86,000 | – | 11,098 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Prosight Management, LP | 829,042 | $9,376,000 | 5.61% |
P.A.W. CAPITAL CORP | 120,000 | $1,357,000 | 1.24% |
Nantahala Capital Management | 2,539,700 | $28,724,000 | 1.01% |
Slate Path Capital LP | 1,483,619 | $16,780,000 | 0.88% |
SANDERS MORRIS HARRIS LLC | 359,113 | $4,416,000 | 0.76% |
APOGEM CAPITAL LLC | 62,295 | $705,000 | 0.46% |
Robertson Stephens Wealth Management, LLC | 478,500 | $5,411,000 | 0.46% |
Bleichroeder LP | 200,000 | $2,262,000 | 0.35% |
ADVISORY RESEARCH INC | 257,225 | $2,909,000 | 0.23% |
Granite Point Capital Management, L.P. | 110,000 | $1,244,000 | 0.21% |